Press Release

Cipla announces Q1 FY 1213 Unaudited Financial Results


Key Financial & Performance Highlights Q1 FY1213 vis-a-vis Q1 FY1112:

- Gross revenues grew by 23.6% to Rs. 2012 cr, up from Rs. 1628 cr in Q1 FY1112
- Operating margins grew by 47.1% to Rs. 563 cr, up from Rs. 383 cr in Q1 FY1112
- Profit after tax grew by 58.2% to Rs. 401 cr during Q1 FY1213, up from Rs. 253 cr (Q1 FY1112)
Profit & Loss Highlights:

- Material cost at 37.6% of Total Sales decreased by 4.9% during Q1 FY1213 as compared to Q1 FY1112.
- Operating margins increased by 47.1% and is at 28.0% of Income from Operations during Q1 FY1213 as compared to 23.5% during Q1 FY1112.
- Profit after tax increased by 58.2% to Rs. 401 cr during Q1 FY1213 as compared to Rs. 253 cr during Q1 FY1112.

Performance Review:

Domestic business:

- Domestic revenues grew by 30.4% to Rs.970 cr during Q1 FY1213, up from Rs. 744 cr during Q1 FY1112.
- The growth in domestic revenues was largely on account of growth in anti-asthma and anti-biotics therapy segments.

International business:

- Exports of formulations grew by 23.0% to Rs. 810 cr during Q1 FY1213, up from Rs. 659 cr during Q1 FY1112.
- Exports of APIs grew by 2.0% to Rs. 168 cr during Q1 FY1213, from Rs. 171 cr during Q1 FY1112.
- The growth in export revenues was primarily due to growth in anti-depressants & anti-cancer segments.

About Cipla:
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US $ 1.4 billion, Cipla serves doctors and patients in over 180 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (www.cipla.com).

Media Contact:

<table>
<thead>
<tr>
<th>Finance</th>
<th>Corporate Communications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajay Luharuka</td>
<td>Antara Mukherjee</td>
</tr>
<tr>
<td>Contact No.: 022 – 23025435</td>
<td>Contact No.: 022 – 23025810</td>
</tr>
<tr>
<td>E-Mail: <a href="mailto:ajay@cipla.com">ajay@cipla.com</a></td>
<td>E-Mail: <a href="mailto:antara.mukherjee@cipla.com">antara.mukherjee@cipla.com</a></td>
</tr>
<tr>
<td></td>
<td>Jaisingh Balakrishnan</td>
</tr>
<tr>
<td></td>
<td>Contact No.: 022 - 23025813</td>
</tr>
<tr>
<td></td>
<td>E-Mail: <a href="mailto:jaisingh.krishnan@cipla.com">jaisingh.krishnan@cipla.com</a></td>
</tr>
</tbody>
</table>